Alpine Immune Sciences Inc. (ALPN)
Company Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.
Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.
The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products.
Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
| Country | United States |
| IPO Date | Jun 17, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 142 |
| CEO | Dr. Mitchell H. Gold M.D. |
Advertisement
Contact Details
Address: 188 East Blaine Street Seattle, Washington United States | |
| Website | https://www.alpineimmunesciences.com |
Stock Details
| Ticker Symbol | ALPN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001626199 |
| CUSIP Number | 02083G100 |
| ISIN Number | US02083G1004 |
| Employer ID | 20-8969493 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mitchell H. Gold M.D. | Executive Chairman & Chief Executive Officer |
| M. Christina Yi | Chief Technology Officer |
| Paul Rickey | Senior Vice President, Chief Financial Officer, Treasurer & Secretary |
| Dr. Andrew Seth Sandler M.D. | Chief Medical Officer |
| Dr. Remy Durand Ph.D. | Chief Business Officer |
| Dr. Stanford Peng M.D., Ph.D. | President and Head of Research & Development |
| Michelle Greenblatt | Director of Investor Relations & Corporate Communications |
| Ulrich Martin Fuhs | Vice President of Finance & Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| May 30, 2024 | 15-12G | Filing |
| May 21, 2024 | SC 13D/A | [Amend] Filing |
| May 21, 2024 | SC 13D/A | [Amend] Filing |
| May 20, 2024 | 4 | Filing |
| May 20, 2024 | 4 | Filing |
| May 20, 2024 | 4 | Filing |
| May 20, 2024 | 4 | Filing |
| May 20, 2024 | 4 | Filing |
| May 20, 2024 | 4 | Filing |